Showing results (141-150 of 165) with videos related to

Sort By:
Pageof 17
Advanced Materials (Deerfield Beach, Fla.)|August 2, 2012
Large work function shift of gold induced by a novel perfluorinated azobenzene-based self-assembled monolayerNúria Crivillers, Silvio Osella, Colin Van Dyck, et al.
The Journal of Clinical Endocrinology and Metabolism|February 1, 2013
Tryptophan hydroxylase autoantibodies as markers of a distinct autoimmune gastrointestinal component of autoimmune polyendocrine syndrome type 1R Scarpa, R Alaggio, L Norberto, et al.
Physical Chemistry Chemical Physics : PCCP|June 23, 2011
Photoinduced work function changes by isomerization of a densely packed azobenzene-based SAM on Au: a joint experimental and theoretical studyN Crivillers, A Liscio, F Di Stasio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 8, 2012
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?D Santini, B Vincenzi, R Addeo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 26, 2015
Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord OvestC Cremolini, F Loupakis, C Antoniotti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 11, 2016
FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trialsC Cremolini, F Loupakis, G Masi, et al.
British Journal of Cancer|July 16, 2009
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancerF Loupakis, A Ruzzo, C Cremolini, et al.
American Journal of Medical Genetics. Part A|November 15, 2015
Craniosynostosis in 10q26 deletion patients: A consequence of brain underdevelopment or altered suture biology?Ágatha Cristhina Faria, Eliete Rabbi-Bortolini, Maria R G O Rebouças, et al.
The Pharmacogenomics Journal|December 24, 2008
Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancerF Graziano, A Ruzzo, E Canestrari, et al.
Breast Cancer Research and Treatment|February 23, 2026
Prognostic significance of circulating tumor DNA in early breast cancer: a systematic review and meta-analysisL Sisca, M G Polito, M Silletta, et al.
Pageof 17